Following the recent Nature Medicine publication of lessons from the NCI-MATCH trial, two new podcasts discuss the pitfalls and promises of precision oncology—and opportunities to guide the field as it moves forward
Reflections on the spring conference season, including highlights from the recent Group Meeting; updates on the ComboMATCH precision medicine initiative
Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019
The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.